Xtandi – pharmaceutical daily

January 23, 2019 Off

Trovagene expands the use of Onvansertib

Trovagene has expanded the use of Onvansertib to enable it for combination therapies with anti-androgen drugs, like Zytiga, Xtandi and Erledea to treat castrate-resistant prostate cancer.

December 15, 2016 Off

Pfizer/Astellas’s cancer drug study fails

By Dino Mustafić

Pfizer and Astellas Pharma have announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with…

October 24, 2016 Off

Astellas’s and Pfizer’s cancer drug gets new product label data

By Dino Mustafić

Astellas Pharma and Pfizer have announced the FDA approved a supplemental New …